In time, the work could help to identify the many forms of autism that make up the spectrum. This is crucial information when those with ASD are administered drugs for a clinical trial. If a gene variant occurs only in one subset of people with ASD but a drug that compensates for that variant is tested across a broader spectrum, then the drug “would appear to be a failure even if it responded to everyone it was meant to respond to,” says Greg Farber, director of technology, development and co-ordination at the U.S. National Institute of Mental Health in Bethesda, Md.Learn more:http://m.theglobeandmail.com/life/health-and-fitness/health/how-canadian-researchers-have-gained-greater-insight-into-human-nature/article19273969/?service=mobile

Questions? Contact Us!

Can't find what you're looking for? Contact Us